The second quarter is expected to be rife with news regarding Food and Drug Administration approval decisions on a biosimilar for rituximab and two pending applications for trastuzumab. Although biosimilars have not generated much news of importance lately, we wrap up the week with some items of interest. First, Celltrion estimates that it will conclude … Continue reading Celltrion and Inflectra, Mylan and Botox, and a Biosimilar Blooper →